Arvaya Healthcare Limited announces an acquisition

The SIGPL transaction cannot yet be valued on an EV/EBITDA basis from the disclosed terms. The announcement identifies SIGPL as Sushodha Institute of Gastroenterology Private Limited—not IG Petrochemicals—and proposes issuing 38,71,854 Arvaya shares to SIGPL shareholders as non-cash consideration. It does not state SIGPL’s audited revenue, EBITDA, net debt, transaction consideration, or implied enterprise value.^[1]

SIGPL and Arvaya valuation snapshot

The 29.11x figure is an annualised Q1 FY27 trading proxy, not a trailing-twelve-month multiple, because TTM EBITDA is not reported. It should therefore be treated cautiously, particularly since the market capitalisation is as of 16 October while the operating denominator is for the quarter ended June 2026.

For reference, Arvaya’s June 2026 fair-valuation report selected a 12.85x EV/EBITDA multiple after applying a 10% size discount to the comparable-company median.^[4] On the above annualised Q1 basis, Arvaya’s market-implied multiple is therefore about 2.27x the report’s selected multiple—but this is a benchmark comparison, not the valuation assigned to SIGPL.

Analytical conclusion: the preferential allotment appears economically assessable only after Arvaya discloses the share-swap pricing or consideration value and SIGPL’s audited EBITDA and net debt. Until then, the transaction’s implied SIGPL EV/EBITDA—and whether it is above or below Arvaya’s current trading proxy—cannot be calculated without inventing a valuation input.

Anticipated dilution: The proposed allotment of 3,871,854 equity shares against the existing 48,021,857 shares implies 7.46% dilution of the post-issue equity:

• Post-issue shares: 48,021,857 + 3,871,854 = 51,893,711
• Dilution: 3,871,854 / 51,893,711 = 7.46%

On a pre-issue share-count basis, the new shares equal 8.06% of existing equity. The standard post-issue dilution measure is 7.46%.

Allottees: The proposed shares are to be issued to the shareholders of Sushodha Institute of Gastroenterology Private Limited (SIGPL) as consideration other than cash, indicating acquisition-related or strategic transaction counterparties rather than a cash fundraising exercise. ^[1]

The cited announcement does not identify the individual allottees or state that they are existing promoters. Therefore, the available disclosure supports the presence of SIGPL shareholders as proposed allottees, but does not establish that any existing promoter is included.

Verdict

SIGPL is best characterised as a horizontal specialty-service expansion within healthcare, not vertical integration. It adds gastroenterology capability to Arvaya Healthcare’s emerging hospital and wellness portfolio. It is not demonstrably a geographic expansion, because SIGPL’s location and geographic revenue exposure are not disclosed in the acquisition filing. The separate move of Arvaya’s registered office from Assam to Maharashtra should not be treated as evidence of SIGPL-related geographic expansion. ^[1]

Fit with Arvaya’s current portfolio

Arvaya’s FY26 disclosures record 100% acquisitions of Health Secure Hospitals Private Limited and Arvaya Health and Wellness Private Limited. ^[5] Against that backdrop, acquiring Sushodha Institute of Gastroenterology Private Limited would deepen the company’s healthcare-delivery and specialty-care offering rather than introduce an unrelated business line. ^[6]

However, the financial disclosures do not provide a segment-wise revenue or profit split for hospitals, wellness, or specialty care. Therefore, the alignment is currently strategic and thematic, not yet measurable in terms of segment contribution, margins, capacity, or patient volumes.

The transaction is also not yet equivalent to a reported operating contribution: Arvaya announced a proposed preferential allotment of 3,871,854 shares to SIGPL shareholders as non-cash consideration, with the board scheduled to consider the allotment on 24 October 2026. ^[6]

Vertical integration versus geographic expansion

• Vertical integration: unlikely on disclosed facts. The target appears to operate at the same healthcare-service level as Arvaya’s hospital and wellness assets. The filing does not identify an upstream pharmaceutical, diagnostics, medical-supply, insurance, or distribution asset. The more accurate description is horizontal integration by specialty.
• Geographic expansion: unproven. The filing identifies SIGPL but does not state its operating location, catchment area, facilities, or revenue by geography. Consequently, the transaction cannot be classified as a geographic roll-up.
• Corporate domicile change is separate. Arvaya’s reported proposal to shift its registered office from Assam to Maharashtra does not establish that SIGPL itself expands Arvaya’s geographic footprint. ^[1]

Peer comparison

A reliable comparison with recent mid-cap healthcare peer M&A therefore cannot be made from the cited disclosures. The available evidence supports a narrower conclusion: SIGPL is a specialty-led expansion of Arvaya’s healthcare platform, financed through a share-swap structure, with neither vertical integration nor geographic diversification established yet. The key missing evidence is SIGPL’s location, operating scale, specialty capacity, financial contribution, and the post-transaction segment reporting structure.